SLC5A2 and diabetes mellitus: Recently, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduced the risk of worsening HF or death from cardiovascular causes, possibly through glucose-independent mechanisms, regardless of the presence or absence of type 2 diabetes mellitus [12].